ICU Medical, Inc. (ICUI)
Nasdaq · Healthcare · Medical Instruments & Supplies
$161.40+1.27%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $4.0B
- P/E (trailing)
- 135.6
- Forward P/E
- 16.7
- 52-week range
- $112.50 – $192.85
- 52-week change
- +34.95%
- EPS (trailing)
- $1.19
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $2.2B (−6.33%)
- Net income
- $732K
- Operating margin
- 1.9%
- Diluted EPS
- $0.03
- Free cash flow
- $91.8M
From the company’s annual report on SEC EDGAR.
About ICU Medical, Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options.
Headquarters: San Clemente, United States · 13,000 employees · icumed.com